Description And Uses

---

Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Tirzepatide is administered via subcutaneous injections (under the skin). It is sold under the brand names Mounjaro for diabetes treatment, and Zepbound for weight loss.

Tirzepatide is a gastric inhibitory polypeptide receptor and GLP-1 receptor agonist. The most common side effects include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain.

Tirzepatide was approved for treatment of diabetes in the United States in May 2022, in the European Union in September 2022, in Canada in November 2022, and in Australia in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. It was approved by the FDA for weight loss in November 2023. In November 2023, the UK Medicines and Healthcare products Regulatory Agency revised the indication for t irzepatide to include treatment for weight loss.

Tirzepatide is indicated to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

]

Tirzepatide is also indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management.

Tirzepatide has demonstrated significant benefits in obese patients with a common type of heart failure, preserved ejection fraction (HFpEF) in a Phase 3 trial. Over two years, tirzepatide reduced the risk of major complications, including urgent heart failure visits, hospitalizations, increased diuretic treatment, and cardiovascular-related deaths, by 38% compared to placebo. This makes tirzepatide the second GLP-1 drug to show positive results in this area, following semaglutide, to date.